Novartis的关于ASCVD病人的Leqvio第3阶段研究显示,LDL胆固醇大幅降低。 Novartis' phase three study of Leqvio for ASCVD patients showed significant LDL cholesterol reduction.

Novartis的关于胆固醇管理药物的第三阶段研究Leqvio显示,独立治疗ASCVD病人取得了积极成果。 Novartis' phase three study of cholesterol-management drug, Leqvio, showed positive results as a standalone treatment for ASCVD patients. 该试验达到主要终点,显示显著的LDL胆固醇降低. The trial met its primary endpoints, demonstrating significant LDL cholesterol reduction. 诺华公司计划向监管机构展示并分享这些结果. Novartis plans to present the results and share them with regulatory agencies. 莱克维奥正在进行额外的ASCVD预防研究,预计在2024-2027年之间取得结果. Leqvio is being explored in additional studies for ASCVD prevention, with results expected between 2024-2027.